Skip to main content

Advertisement

Table 2 Patients reporting mild, moderate or severe treatment-related adverse events during treatment with lanreotide autogel

From: Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

Organ system Severe Moderate Mild Total
Any 1 (3.3) 8 (26.7) 17 (56.7) 19 (63.3)
Gastrointestinal 1 (3.3) 4 (13.3) 12 (40.0) 13 (43.3)
General and 0 5 (16.7) 9 (30.0) 10 (33.3)
injection site
Neurological 0 0 3 (10.0) 3 (10.0)
Metabolic and nutritional 0 1 (3.3) 1 (3.3) 2 (6.7)
Infections 0 1 (3.3) 0 1 (3.3)
Skin and subcutaneous tissue 0 0 1 (3.3) 1 (3.3)
Ear and labyrinth 0 0 1 (3.3) 1 (3.3)
Renal/urinary tract 0 1 (3.3)a 0 1 (3.3)
Reproductive system and breast 0 0 1 (3.3) 1 (3.3)
Vascular 0 0 1 (3.3) 1 (3.3)
  1. Data are number (%) of patients.
  2. aEvent was serious AE (acute renal failure) but resolved without sequelae.